Concepts (266)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Women's Health | 14 | 2021 | 247 | 1.690 |
Why?
|
Metabolic Syndrome | 6 | 2020 | 68 | 1.680 |
Why?
|
Adiposity | 8 | 2018 | 47 | 1.480 |
Why?
|
Menopause | 9 | 2021 | 135 | 1.460 |
Why?
|
Intra-Abdominal Fat | 6 | 2021 | 42 | 1.300 |
Why?
|
Obesity | 6 | 2018 | 290 | 1.180 |
Why?
|
Diabetes Mellitus, Type 2 | 6 | 2015 | 201 | 1.070 |
Why?
|
Cardiovascular Diseases | 8 | 2021 | 411 | 0.980 |
Why?
|
Ecosystem | 1 | 2023 | 27 | 0.900 |
Why?
|
Diabetes Mellitus | 2 | 2023 | 140 | 0.890 |
Why?
|
Thrombosis | 2 | 2014 | 59 | 0.850 |
Why?
|
Middle Aged | 36 | 2021 | 9960 | 0.850 |
Why?
|
Obesity, Abdominal | 4 | 2015 | 22 | 0.820 |
Why?
|
Adrenal Gland Diseases | 2 | 2012 | 3 | 0.750 |
Why?
|
Female | 43 | 2021 | 16412 | 0.730 |
Why?
|
Atrial Fibrillation | 2 | 2014 | 186 | 0.730 |
Why?
|
Abdominal Fat | 3 | 2021 | 10 | 0.660 |
Why?
|
Diet Therapy | 1 | 2018 | 9 | 0.640 |
Why?
|
Weight Reduction Programs | 1 | 2018 | 17 | 0.630 |
Why?
|
Humans | 47 | 2023 | 29814 | 0.630 |
Why?
|
Risk Factors | 20 | 2021 | 2465 | 0.610 |
Why?
|
Behavior Therapy | 1 | 2018 | 77 | 0.610 |
Why?
|
Atherosclerosis | 3 | 2021 | 75 | 0.600 |
Why?
|
Exercise Therapy | 1 | 2018 | 112 | 0.590 |
Why?
|
Hydrocortisone | 3 | 2012 | 43 | 0.580 |
Why?
|
Testosterone | 2 | 2014 | 32 | 0.570 |
Why?
|
Adult | 22 | 2021 | 8741 | 0.570 |
Why?
|
Waist-Height Ratio | 1 | 2016 | 6 | 0.560 |
Why?
|
Metabolic Diseases | 1 | 2016 | 14 | 0.560 |
Why?
|
United States | 15 | 2021 | 2344 | 0.560 |
Why?
|
Mass Screening | 1 | 2016 | 180 | 0.500 |
Why?
|
Cognition Disorders | 2 | 2020 | 1032 | 0.480 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2014 | 42 | 0.460 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2013 | 11 | 0.440 |
Why?
|
Adrenal Cortex Function Tests | 1 | 2012 | 1 | 0.430 |
Why?
|
Prevalence | 4 | 2016 | 494 | 0.420 |
Why?
|
Hemodynamics | 1 | 2012 | 90 | 0.420 |
Why?
|
Liver Cirrhosis | 1 | 2012 | 60 | 0.410 |
Why?
|
Postmenopause | 6 | 2019 | 61 | 0.410 |
Why?
|
Adrenocorticotropic Hormone | 2 | 2009 | 9 | 0.410 |
Why?
|
Lipoproteins, HDL | 3 | 2014 | 30 | 0.400 |
Why?
|
Blood Glucose Self-Monitoring | 2 | 2009 | 4 | 0.390 |
Why?
|
Carotid Intima-Media Thickness | 2 | 2021 | 24 | 0.390 |
Why?
|
Perimenopause | 3 | 2021 | 24 | 0.380 |
Why?
|
Biomarkers | 5 | 2020 | 704 | 0.370 |
Why?
|
Longitudinal Studies | 9 | 2020 | 1462 | 0.370 |
Why?
|
Follow-Up Studies | 9 | 2020 | 1859 | 0.360 |
Why?
|
Diastole | 1 | 2010 | 36 | 0.350 |
Why?
|
Absorptiometry, Photon | 3 | 2015 | 84 | 0.350 |
Why?
|
Adrenal Insufficiency | 1 | 2009 | 7 | 0.350 |
Why?
|
Cardiomyopathies | 1 | 2010 | 31 | 0.350 |
Why?
|
Vitamin D | 1 | 2010 | 32 | 0.350 |
Why?
|
Blood Glucose | 5 | 2020 | 112 | 0.340 |
Why?
|
Reproducibility of Results | 4 | 2014 | 802 | 0.320 |
Why?
|
Pituitary Diseases | 1 | 2008 | 3 | 0.320 |
Why?
|
Hypothalamic Diseases | 1 | 2008 | 6 | 0.320 |
Why?
|
Algorithms | 3 | 2023 | 400 | 0.320 |
Why?
|
Hypertension | 4 | 2021 | 272 | 0.310 |
Why?
|
Body Mass Index | 5 | 2018 | 425 | 0.300 |
Why?
|
Socioeconomic Factors | 4 | 2023 | 329 | 0.300 |
Why?
|
Prospective Studies | 6 | 2020 | 1823 | 0.290 |
Why?
|
Depression | 3 | 2018 | 472 | 0.290 |
Why?
|
Population Surveillance | 2 | 2020 | 118 | 0.290 |
Why?
|
Cohort Studies | 7 | 2020 | 1952 | 0.280 |
Why?
|
Exercise | 3 | 2018 | 474 | 0.270 |
Why?
|
Sensitivity and Specificity | 3 | 2014 | 558 | 0.270 |
Why?
|
Prognosis | 3 | 2020 | 874 | 0.270 |
Why?
|
Male | 13 | 2020 | 15851 | 0.270 |
Why?
|
Risk Assessment | 3 | 2020 | 683 | 0.270 |
Why?
|
Ketone Bodies | 1 | 2005 | 5 | 0.260 |
Why?
|
Incidence | 5 | 2020 | 759 | 0.250 |
Why?
|
ROC Curve | 3 | 2009 | 140 | 0.240 |
Why?
|
Diet | 2 | 2019 | 172 | 0.230 |
Why?
|
Economic Development | 1 | 2023 | 4 | 0.230 |
Why?
|
Estradiol | 4 | 2021 | 47 | 0.230 |
Why?
|
Developing Countries | 1 | 2023 | 21 | 0.230 |
Why?
|
Insulin | 2 | 2011 | 92 | 0.230 |
Why?
|
Chicago | 5 | 2014 | 867 | 0.230 |
Why?
|
Pregnanediol | 2 | 2021 | 6 | 0.230 |
Why?
|
Luteinizing Hormone | 2 | 2021 | 9 | 0.230 |
Why?
|
Pharmacoepidemiology | 2 | 2020 | 5 | 0.230 |
Why?
|
Life Style | 2 | 2018 | 212 | 0.220 |
Why?
|
Energy Intake | 3 | 2019 | 66 | 0.220 |
Why?
|
Atrial Appendage | 2 | 2014 | 45 | 0.220 |
Why?
|
Hypoglycemic Agents | 1 | 2003 | 57 | 0.210 |
Why?
|
Waist Circumference | 4 | 2016 | 36 | 0.210 |
Why?
|
Energy Metabolism | 2 | 2018 | 53 | 0.210 |
Why?
|
Aged | 11 | 2020 | 9620 | 0.210 |
Why?
|
Stroke Volume | 2 | 2014 | 61 | 0.200 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2018 | 298 | 0.200 |
Why?
|
Menstrual Cycle | 2 | 2021 | 32 | 0.200 |
Why?
|
Hyperglycemia | 2 | 2020 | 34 | 0.200 |
Why?
|
Progesterone | 1 | 2021 | 21 | 0.190 |
Why?
|
Cosyntropin | 2 | 2012 | 3 | 0.190 |
Why?
|
Carotid Artery Diseases | 1 | 2021 | 44 | 0.190 |
Why?
|
Multimorbidity | 1 | 2020 | 8 | 0.180 |
Why?
|
Insulin Resistance | 4 | 2011 | 61 | 0.180 |
Why?
|
Cholesterol, HDL | 3 | 2011 | 30 | 0.180 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2020 | 96 | 0.180 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 64 | 0.170 |
Why?
|
Seasons | 1 | 2019 | 31 | 0.170 |
Why?
|
Cerebral Hemorrhage | 1 | 2020 | 131 | 0.170 |
Why?
|
Antidepressive Agents | 1 | 2019 | 103 | 0.160 |
Why?
|
Appetite | 1 | 2018 | 5 | 0.160 |
Why?
|
Antihypertensive Agents | 1 | 2019 | 85 | 0.160 |
Why?
|
Fractures, Bone | 1 | 2019 | 75 | 0.160 |
Why?
|
Body Weight | 1 | 2018 | 132 | 0.150 |
Why?
|
Weight Gain | 1 | 2018 | 66 | 0.150 |
Why?
|
Chronic Disease | 1 | 2020 | 508 | 0.150 |
Why?
|
Weight Loss | 1 | 2018 | 101 | 0.150 |
Why?
|
Hormones | 1 | 2017 | 9 | 0.150 |
Why?
|
Genetic Predisposition to Disease | 2 | 2018 | 433 | 0.150 |
Why?
|
Time Factors | 4 | 2020 | 1641 | 0.150 |
Why?
|
Depressive Disorder | 1 | 2018 | 191 | 0.150 |
Why?
|
Social Support | 1 | 2018 | 186 | 0.140 |
Why?
|
Sleep Wake Disorders | 1 | 2018 | 148 | 0.140 |
Why?
|
Beverages | 1 | 2016 | 10 | 0.140 |
Why?
|
Retrospective Studies | 5 | 2014 | 3325 | 0.140 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 532 | 0.140 |
Why?
|
Cross-Sectional Studies | 3 | 2009 | 970 | 0.130 |
Why?
|
Child | 3 | 2009 | 1377 | 0.130 |
Why?
|
Climacteric | 1 | 2015 | 10 | 0.130 |
Why?
|
False Positive Reactions | 1 | 2015 | 34 | 0.130 |
Why?
|
Estrogens | 1 | 2015 | 37 | 0.130 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2015 | 18 | 0.130 |
Why?
|
Immunoassay | 1 | 2015 | 42 | 0.130 |
Why?
|
Carbonated Beverages | 1 | 2014 | 2 | 0.120 |
Why?
|
Research Report | 1 | 2014 | 7 | 0.120 |
Why?
|
Sweetening Agents | 1 | 2014 | 7 | 0.120 |
Why?
|
Waist-Hip Ratio | 1 | 2014 | 16 | 0.120 |
Why?
|
Birth Weight | 1 | 2015 | 34 | 0.120 |
Why?
|
Tomography, X-Ray Computed | 3 | 2014 | 778 | 0.120 |
Why?
|
Age Factors | 3 | 2020 | 853 | 0.120 |
Why?
|
Meals | 1 | 2014 | 12 | 0.120 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 2015 | 25 | 0.120 |
Why?
|
Illinois | 2 | 2013 | 241 | 0.120 |
Why?
|
Oligomenorrhea | 1 | 2014 | 1 | 0.120 |
Why?
|
Hyperandrogenism | 1 | 2014 | 1 | 0.120 |
Why?
|
Self Report | 3 | 2020 | 221 | 0.120 |
Why?
|
Personal Satisfaction | 1 | 2014 | 48 | 0.110 |
Why?
|
Echocardiography, Transesophageal | 1 | 2014 | 46 | 0.110 |
Why?
|
Body Image | 1 | 2014 | 31 | 0.110 |
Why?
|
Employment | 1 | 2013 | 42 | 0.110 |
Why?
|
Heart Valve Diseases | 1 | 2013 | 23 | 0.110 |
Why?
|
Body Fat Distribution | 1 | 2012 | 12 | 0.110 |
Why?
|
Blood Pressure | 4 | 2019 | 252 | 0.100 |
Why?
|
Logistic Models | 3 | 2019 | 410 | 0.100 |
Why?
|
Motor Activity | 2 | 2018 | 372 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 177 | 0.100 |
Why?
|
Cognitive Dysfunction | 1 | 2021 | 969 | 0.100 |
Why?
|
Up-Regulation | 1 | 2012 | 173 | 0.100 |
Why?
|
Proportional Hazards Models | 1 | 2012 | 346 | 0.100 |
Why?
|
Neuropsychological Tests | 2 | 2021 | 1270 | 0.100 |
Why?
|
Subcutaneous Fat, Abdominal | 1 | 2011 | 2 | 0.100 |
Why?
|
Ultrasonography | 1 | 2013 | 224 | 0.100 |
Why?
|
Breast Neoplasms | 2 | 2015 | 352 | 0.090 |
Why?
|
Infant | 2 | 2009 | 542 | 0.090 |
Why?
|
Calcifediol | 1 | 2010 | 2 | 0.090 |
Why?
|
25-Hydroxyvitamin D 2 | 1 | 2010 | 3 | 0.090 |
Why?
|
Pericardium | 1 | 2010 | 20 | 0.090 |
Why?
|
Child, Preschool | 2 | 2009 | 654 | 0.090 |
Why?
|
Metyrapone | 1 | 2009 | 1 | 0.090 |
Why?
|
Glucose Tolerance Test | 1 | 2009 | 10 | 0.090 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2010 | 44 | 0.090 |
Why?
|
Particle Size | 1 | 2010 | 69 | 0.090 |
Why?
|
Reference Standards | 1 | 2009 | 33 | 0.090 |
Why?
|
Antimetabolites | 1 | 2009 | 14 | 0.090 |
Why?
|
Aged, 80 and over | 3 | 2018 | 4930 | 0.090 |
Why?
|
Alcohol Drinking | 1 | 2010 | 77 | 0.090 |
Why?
|
Follicle Stimulating Hormone | 2 | 2021 | 21 | 0.080 |
Why?
|
Hospitals, Public | 1 | 2009 | 31 | 0.080 |
Why?
|
Regression Analysis | 1 | 2010 | 298 | 0.080 |
Why?
|
Health Behavior | 1 | 2010 | 159 | 0.080 |
Why?
|
Fasting | 1 | 2008 | 13 | 0.080 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2008 | 14 | 0.080 |
Why?
|
Urban Population | 1 | 2009 | 143 | 0.080 |
Why?
|
Severity of Illness Index | 1 | 2012 | 1126 | 0.080 |
Why?
|
Glucocorticoids | 1 | 2008 | 69 | 0.080 |
Why?
|
Hypercalcemia | 1 | 2007 | 12 | 0.070 |
Why?
|
Burns | 1 | 2007 | 21 | 0.070 |
Why?
|
Carotid Arteries | 2 | 2021 | 54 | 0.070 |
Why?
|
Linear Models | 2 | 2018 | 258 | 0.070 |
Why?
|
Adolescent | 2 | 2009 | 2332 | 0.070 |
Why?
|
Patient Education as Topic | 1 | 2007 | 161 | 0.070 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2007 | 194 | 0.060 |
Why?
|
Intensive Care Units | 1 | 2007 | 312 | 0.060 |
Why?
|
Lamin Type A | 1 | 2004 | 1 | 0.060 |
Why?
|
Lipodystrophy | 1 | 2004 | 1 | 0.060 |
Why?
|
Acyltransferases | 1 | 2004 | 3 | 0.060 |
Why?
|
GTP-Binding Protein gamma Subunits | 1 | 2004 | 2 | 0.060 |
Why?
|
Polymorphism, Genetic | 1 | 2004 | 74 | 0.060 |
Why?
|
Odds Ratio | 2 | 2015 | 286 | 0.060 |
Why?
|
Young Adult | 1 | 2009 | 1966 | 0.060 |
Why?
|
Gluconeogenesis | 1 | 2003 | 4 | 0.060 |
Why?
|
Chemistry, Pharmaceutical | 1 | 2003 | 11 | 0.060 |
Why?
|
Hyperlipidemias | 1 | 2003 | 22 | 0.060 |
Why?
|
Fatty Acids | 1 | 2003 | 39 | 0.050 |
Why?
|
Triglycerides | 2 | 2014 | 45 | 0.050 |
Why?
|
Psychiatric Status Rating Scales | 2 | 2014 | 351 | 0.050 |
Why?
|
Pulse Wave Analysis | 1 | 2021 | 4 | 0.050 |
Why?
|
Ankle Brachial Index | 1 | 2021 | 6 | 0.050 |
Why?
|
Liver | 1 | 2003 | 175 | 0.050 |
Why?
|
Surveys and Questionnaires | 3 | 2015 | 1187 | 0.050 |
Why?
|
Patient Selection | 1 | 2003 | 234 | 0.050 |
Why?
|
Vasomotor System | 1 | 2021 | 5 | 0.050 |
Why?
|
Cognition | 1 | 2009 | 1314 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2003 | 334 | 0.050 |
Why?
|
Affect | 1 | 2021 | 65 | 0.050 |
Why?
|
Morbidity | 1 | 2020 | 63 | 0.050 |
Why?
|
Hypertriglyceridemia | 2 | 2014 | 20 | 0.040 |
Why?
|
Disease Progression | 1 | 2003 | 812 | 0.040 |
Why?
|
Diet Surveys | 1 | 2019 | 18 | 0.040 |
Why?
|
Propensity Score | 1 | 2019 | 34 | 0.040 |
Why?
|
Healthy Aging | 1 | 2018 | 13 | 0.040 |
Why?
|
Genetic Testing | 1 | 2018 | 62 | 0.040 |
Why?
|
Osteoporosis | 1 | 2019 | 84 | 0.040 |
Why?
|
Analysis of Variance | 1 | 2018 | 325 | 0.040 |
Why?
|
Hospitalization | 1 | 2020 | 319 | 0.040 |
Why?
|
Accidental Falls | 1 | 2019 | 117 | 0.040 |
Why?
|
Estrone | 1 | 2017 | 6 | 0.040 |
Why?
|
Corpus Luteum | 1 | 2017 | 4 | 0.040 |
Why?
|
Premenopause | 1 | 2017 | 20 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2018 | 298 | 0.040 |
Why?
|
Sleep | 1 | 2020 | 318 | 0.040 |
Why?
|
Genotype | 1 | 2018 | 399 | 0.040 |
Why?
|
Chromatography, Liquid | 1 | 2015 | 25 | 0.030 |
Why?
|
Tandem Mass Spectrometry | 1 | 2015 | 27 | 0.030 |
Why?
|
E-Selectin | 1 | 2015 | 2 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2015 | 68 | 0.030 |
Why?
|
Androgens | 1 | 2014 | 8 | 0.030 |
Why?
|
Multivariate Analysis | 1 | 2015 | 332 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2015 | 641 | 0.030 |
Why?
|
Myocardial Infarction | 1 | 2014 | 175 | 0.030 |
Why?
|
Tunica Intima | 1 | 2011 | 27 | 0.020 |
Why?
|
Nutrition Policy | 1 | 2010 | 6 | 0.020 |
Why?
|
Dietary Fats | 1 | 2010 | 22 | 0.020 |
Why?
|
Vegetables | 1 | 2010 | 15 | 0.020 |
Why?
|
France | 1 | 2010 | 36 | 0.020 |
Why?
|
Fruit | 1 | 2010 | 24 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2010 | 77 | 0.020 |
Why?
|
Cross-Cultural Comparison | 1 | 2010 | 40 | 0.020 |
Why?
|
Stroke | 1 | 2014 | 294 | 0.020 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2009 | 15 | 0.020 |
Why?
|
Biological Availability | 1 | 2009 | 26 | 0.020 |
Why?
|
Aging | 1 | 2018 | 1630 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2010 | 337 | 0.020 |
Why?
|
Albumins | 1 | 2007 | 35 | 0.020 |
Why?
|
Cholesterol, LDL | 1 | 2007 | 33 | 0.020 |
Why?
|
Knowledge | 1 | 2007 | 19 | 0.020 |
Why?
|
Lipids | 1 | 2007 | 36 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2015 | 3561 | 0.020 |
Why?
|
Length of Stay | 1 | 2007 | 320 | 0.020 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2004 | 8 | 0.020 |
Why?
|
1-Acylglycerol-3-Phosphate O-Acyltransferase | 1 | 2004 | 1 | 0.020 |
Why?
|
Consanguinity | 1 | 2004 | 4 | 0.020 |
Why?
|
Hyperinsulinism | 1 | 2004 | 4 | 0.020 |
Why?
|
Pennsylvania | 1 | 2004 | 14 | 0.020 |
Why?
|
RNA Splice Sites | 1 | 2004 | 3 | 0.020 |
Why?
|
Frameshift Mutation | 1 | 2004 | 5 | 0.020 |
Why?
|
Linkage Disequilibrium | 1 | 2004 | 39 | 0.010 |
Why?
|
Exons | 1 | 2004 | 37 | 0.010 |
Why?
|
Homozygote | 1 | 2004 | 22 | 0.010 |
Why?
|
Haplotypes | 1 | 2004 | 58 | 0.010 |
Why?
|
Alleles | 1 | 2004 | 216 | 0.010 |
Why?
|
Calcium | 1 | 2007 | 496 | 0.010 |
Why?
|
Phenotype | 1 | 2004 | 362 | 0.010 |
Why?
|